# US 8,541,547 B2 · Methods and compositions for tumor vaccination and therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,547 B2
- Document ID: US8541547B2
- Status: Granted
- Kind: B2
- Application number: 13/465,391
- Filed: 2012-05-07
- Published: 2012-09-13
- Granted: 2013-09-24
- Earliest claimed: 2007-07-05
- Assignees: The Rockefeller University
- Applicants: Robert B. Darnell
- Inventors: Robert B. Darnell
- Web page: https://patentgrep.com/patent/US8541547B2

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

## Claims

### Claim 1

A composition comprising (i) an isolated peptide comprising the sequence of SEQ ID NO: 3 and (ii) a HuD peptide, wherein the HuD peptide consists of the amino acid sequence of SEQ ID NO: 146 or 147.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition further comprises a Cdr2 peptide that comprises a sequence selected from the group consisting of SEQ ID NOs: 2 and 4-145.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition further comprises an adjuvant.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the isolated peptide is linked to a helper peptide, lipid, or liposome.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition further comprises an antibody that is able to specifically recognize and bind to a cdr2 or HuD peptide.

### Claim 6 (depends on 1)

A cell composition comprising the composition of claim 1 and a plurality of cells.

### Claim 7 (depends on 6)

The cell composition of claim 6, further comprising a medium.

### Claim 8 (depends on 6)

The cell composition of claim 6, wherein the cells comprises lymphocytes.

### Claim 9 (depends on 6)

The cell composition of claim 6, wherein the lymphocytes are selected from the group consisting of cdr2 antigen specific CD8+cytotoxic T lymphocytes and HuD antigen specific CD8+cytotoxic T lymphocytes.